Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Shares of TRVN opened at $1.93 on Monday. The firm has a market cap of $1.66 million, a P/E ratio of -0.04 and a beta of 1.08. Trevena has a twelve month low of $1.13 and a twelve month high of $19.23. The firm’s 50 day moving average price is $3.19 and its two-hundred day moving average price is $5.75.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The business had revenue of $0.28 million during the quarter. On average, sell-side analysts anticipate that Trevena will post -32.25 earnings per share for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.